TCM Biotech International Corp. (TPEX:4169)
179.00
-2.00 (-1.10%)
At close: Dec 5, 2025
TCM Biotech International Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 21.08 | 21.01 | 18.57 | 18.27 | 1.87 | 25.54 | Upgrade
|
| Depreciation & Amortization | 22.13 | 22.03 | 20.2 | 18.41 | 16.46 | 14.81 | Upgrade
|
| Other Amortization | 1.83 | 1.84 | 1.69 | 1.59 | 1.59 | 0.26 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.98 | -0.72 | -0.8 | - | -0.91 | -1.35 | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.67 | - | - | - | - | - | Upgrade
|
| Stock-Based Compensation | - | - | 1.95 | - | 1.73 | - | Upgrade
|
| Provision & Write-off of Bad Debts | -1.76 | -0.69 | - | 0.48 | - | 0.75 | Upgrade
|
| Other Operating Activities | -1.39 | 1.33 | 1.02 | 6.19 | -3.14 | 5.31 | Upgrade
|
| Change in Accounts Receivable | -21.96 | 120.47 | -27.69 | -35.13 | -22.2 | -7.62 | Upgrade
|
| Change in Inventory | 3.29 | 50.65 | -13.34 | 4.75 | -3.27 | 9 | Upgrade
|
| Change in Accounts Payable | 7.53 | -43.32 | -18.69 | 24.47 | 18.14 | -4.52 | Upgrade
|
| Change in Unearned Revenue | -0.53 | 0.59 | 2.72 | -20.55 | 1.31 | 18.72 | Upgrade
|
| Change in Other Net Operating Assets | 10.44 | -5.76 | -23.17 | 33.77 | 3.74 | 14 | Upgrade
|
| Operating Cash Flow | 40.36 | 167.42 | -37.54 | 52.24 | 15.33 | 74.9 | Upgrade
|
| Operating Cash Flow Growth | -67.03% | - | - | 240.86% | -79.54% | - | Upgrade
|
| Capital Expenditures | -3.98 | -8 | -3.98 | -3.78 | -4.14 | -2.94 | Upgrade
|
| Sale of Property, Plant & Equipment | 1.82 | 1.28 | 1.33 | - | 1.96 | 1.99 | Upgrade
|
| Sale (Purchase) of Intangibles | -0.34 | -0.35 | -0.94 | -1.51 | -3.58 | -18.74 | Upgrade
|
| Investment in Securities | -130 | -330 | - | -0.09 | - | - | Upgrade
|
| Other Investing Activities | -0.4 | -3.32 | -0.94 | -2.71 | -13.85 | -5.85 | Upgrade
|
| Investing Cash Flow | -132.9 | -340.4 | -4.52 | -8.09 | -19.61 | -25.55 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 44 | - | Upgrade
|
| Long-Term Debt Issued | - | - | 30 | - | - | - | Upgrade
|
| Total Debt Issued | - | - | 30 | - | 44 | - | Upgrade
|
| Short-Term Debt Repaid | - | -44 | - | - | - | -14.63 | Upgrade
|
| Long-Term Debt Repaid | - | -37.09 | -72.08 | -12.55 | -11.94 | -11.11 | Upgrade
|
| Total Debt Repaid | -7.34 | -81.09 | -72.08 | -12.55 | -11.94 | -25.74 | Upgrade
|
| Net Debt Issued (Repaid) | -7.34 | -81.09 | -42.08 | -12.55 | 32.06 | -25.74 | Upgrade
|
| Issuance of Common Stock | - | - | 500 | - | 13.09 | - | Upgrade
|
| Common Dividends Paid | -20.67 | -16.83 | -1.62 | - | -16.92 | -18.8 | Upgrade
|
| Other Financing Activities | - | -0.27 | - | 0.11 | - | 0.16 | Upgrade
|
| Financing Cash Flow | -28.01 | -98.19 | 456.3 | -12.44 | 28.24 | -44.37 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.03 | 0.02 | 0.04 | -0.12 | 0.03 | 0.03 | Upgrade
|
| Net Cash Flow | -120.52 | -271.15 | 414.29 | 31.59 | 23.99 | 5.01 | Upgrade
|
| Free Cash Flow | 36.37 | 159.42 | -41.51 | 48.46 | 11.19 | 71.96 | Upgrade
|
| Free Cash Flow Growth | -68.57% | - | - | 333.15% | -84.45% | - | Upgrade
|
| Free Cash Flow Margin | 5.33% | 23.92% | -4.28% | 6.04% | 1.59% | 9.76% | Upgrade
|
| Free Cash Flow Per Share | 0.62 | 2.70 | -0.78 | 0.99 | 0.23 | 1.49 | Upgrade
|
| Cash Interest Paid | 0.87 | 1.61 | 2.77 | 2.39 | 1.97 | 1.95 | Upgrade
|
| Cash Income Tax Paid | 4.12 | 2.57 | 2.44 | - | 3.53 | 5.28 | Upgrade
|
| Levered Free Cash Flow | - | 146.85 | -42.01 | 63.66 | 11.11 | 30.36 | Upgrade
|
| Unlevered Free Cash Flow | - | 147.85 | -40.28 | 65.15 | 12.34 | 31.57 | Upgrade
|
| Change in Working Capital | -1.22 | 122.63 | -80.18 | 7.3 | -2.28 | 29.58 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.